Nyxoah price target raised to $20 from $17 at Oppenheimer

Oppenheimer raised the firm’s price target on Nyxoah to $20 from $17 and keeps an Outperform rating on the shares. Nyxoah’s DREAM IDE pivotal trial, evaluating the Genio hypoglossal nerve stimulation system in adults with OSA, is expected to publish top-line data for the full cohort in early April, the firm notes. The data release will include a few top-line readouts, including AHI response rate; ODI endpoint; median AHI reduction; and safety data. More comprehensive data is expected to be presented at ISSS, accompanied by a Tier-1 publication with more detail and review of data at a later date, Oppenheimer adds.